A ruthenium-platinum metal complex that binds to sarcin ricin loop RNA and lowers mRNA expression.

IT127 is a dinuclear transition metal complex that contains a Pt(ii) and a Ru(iii) metal center. We have shown that IT127 is significantly more effective in binding the 29-base sarcin ricin loop (SRL) RNA in comparison to Cisplatin, a hallmark anticancer agent. Binding site analysis shows that IT127 prefers purine bases and the GAGA tetraloop region of SRL RNA. Our results with a dihydrofolate reductase (DHFR) model system reveal that IT127 binding to mRNA reduces translation of DHFR enzyme and that the Ru(iii) and Pt(ii) centers in IT127 appear to work in a synergistic manner.

[1]  P. Dyson,et al.  The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions , 2018 .

[2]  W. Youngs,et al.  Recent Developments in the Medicinal Applications of Silver-NHC Complexes and Imidazolium Salts , 2017, Molecules.

[3]  C. Che,et al.  A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo. , 2016, Angewandte Chemie.

[4]  Rong Ma,et al.  Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis. , 2016, Chemical communications.

[5]  S. Lippard,et al.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.

[6]  Jessica L. Childs-Disney,et al.  Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells. , 2016, Annual review of pharmacology and toxicology.

[7]  Jean-Pierre Gillet,et al.  Toward a Better Understanding of the Complexity of Cancer Drug Resistance. , 2016, Annual review of pharmacology and toxicology.

[8]  J. Lazo,et al.  Drugging Undruggable Molecular Cancer Targets. , 2016, Annual review of pharmacology and toxicology.

[9]  V. Lynch,et al.  Targeting antioxidant pathways with ferrocenylated N-heterocyclic carbene supported gold(i) complexes in A549 lung cancer cells , 2015, Chemical science.

[10]  A. Bergamo,et al.  Linking the future of anticancer metal-complexes to the therapy of tumour metastases. , 2015, Chemical Society reviews.

[11]  M. Hemann,et al.  Necroptosis-inducing rhenium(V) oxo complexes. , 2015, Journal of the American Chemical Society.

[12]  Robert N. Azad,et al.  Chemical probing of RNA with the hydroxyl radical at single-atom resolution , 2014, Nucleic acids research.

[13]  V. DeRose,et al.  Platinum-RNA Modifications Following Drug Treatment in S. cerevisiae Identified by Click Chemistry and Enzymatic Mapping , 2014, ACS chemical biology.

[14]  M. Mozzicafreddo,et al.  Arene-ruthenium(II) acylpyrazolonato complexes: apoptosis-promoting effects on human cancer cells. , 2014, Journal of medicinal chemistry.

[15]  Benoît Bertrand,et al.  Caffeine-based gold(I) N-heterocyclic carbenes as possible anticancer agents: synthesis and biological properties. , 2014, Inorganic chemistry.

[16]  S. Braga,et al.  A New Age for Iron: Antitumoral Ferrocenes , 2013 .

[17]  I. Taylor,et al.  RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex. , 2013, Chemical communications.

[18]  Yongfeng Hu,et al.  Hetero-multinuclear ruthenium(III)/platinum(II) complexes that potentially exhibit both antimetastatic and antineoplastic properties. , 2012, Inorganic chemistry.

[19]  Christopher R Chitambar,et al.  Gallium-containing anticancer compounds. , 2012, Future medicinal chemistry.

[20]  J. Pelletier,et al.  Emerging therapeutics targeting mRNA translation. , 2012, Cold Spring Harbor perspectives in biology.

[21]  V. DeRose,et al.  RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae. , 2012, ACS chemical biology.

[22]  M. Disney,et al.  Recent advances in developing small molecules targeting RNA. , 2012, ACS chemical biology.

[23]  J. Sessler,et al.  Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate. , 2011, Bioorganic & medicinal chemistry letters.

[24]  B. Winkel,et al.  DNA interaction studies of tridentate bridged Ru(II)-Pt(II) mixed-metal supramolecules. , 2009, Journal of inorganic biochemistry.

[25]  P. Dyson,et al.  Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.

[26]  S. Lippard,et al.  New metal complexes as potential therapeutics. , 2003, Current opinion in chemical biology.

[27]  P. Michiels,et al.  Targeting RNA: new opportunities to address drugless targets. , 2003, Drug discovery today.

[28]  V. Brabec,et al.  DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. , 2003, Biochemistry.

[29]  E. Meléndez.  Titanium complexes in cancer treatment. , 2002, Critical reviews in oncology/hematology.

[30]  B. Van Houten,et al.  Homodinuclear (Pt,Pt) and heterodinuclear (Ru,Pt) metal compounds as DNA-protein cross-linking agents: potential suicide DNA lesions. , 1993, Biochemistry.

[31]  I. Wool,et al.  The conformation of the sarcin/ricin loop from 28S ribosomal RNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Sato,et al.  Cisplatin inhibits in vitro translation by preventing the formation of complete initiation complex. , 1993, Molecular pharmacology.

[33]  P. Wollenzien,et al.  Use of reverse transcription to determine the exact locations of psoralen photochemical crosslinks in RNA. , 1988, Analytical biochemistry.

[34]  J. Gready.  Dihydrofolate reductase: binding of substrates and inhibitors and catalytic mechanism. , 1980, Advances in pharmacology and chemotherapy.